论文部分内容阅读
目的回顾性分析帕洛诺司琼预防肺癌含铂类药物化疗所致恶心、呕吐的疗效和安全性。方法选择肺癌患者60例,分为帕洛诺司琼(A组)、托烷司琼组(B组),每组30例。分别用帕洛诺司琼和托烷司琼预防化疗所致的恶心、呕吐反应,观察和评价两种止吐药物控制急性呕吐和延迟性呕吐的疗效及不良反应。结果两组预防急性呕吐的控制率差异无统计学意义(P>0.05),A组对延迟性呕吐控制率高于B组(73.3%vs.43.4%)(P<0.05)。两组不良反应主要为便秘和头痛,发生率均低,反应程度轻微。结论帕洛诺司琼预防和控制迟发性化疗相关恶心呕吐的疗效优于托烷司琼,且给药方便,安全性和耐受性好。
Objective To retrospectively analyze the efficacy and safety of palonosetron in the prevention of nausea and vomiting caused by platinum-containing chemotherapy of lung cancer. Methods Sixty patients with lung cancer were selected and divided into palonosetron (group A) and tropisetron (group B), 30 cases in each group. Palonosetron and tropisetron were respectively used to prevent chemotherapy-induced nausea and vomiting reactions. The efficacy and adverse reactions of two antiemetic drugs to control acute vomiting and delayed vomiting were observed and evaluated. Results There was no significant difference in the control rate of acute vomiting between the two groups (P> 0.05). The control rate of delayed emesis in group A was higher than that in group B (73.3% vs.43.4%) (P <0.05). The two groups of adverse reactions mainly constipation and headache, the incidence was low, mild reaction. Conclusions Palonosetron is superior to tropisetron in the prevention and control of delayed chemotherapy-related nausea and vomiting. It is convenient, safe and tolerable.